Work

Supplementary Figure S3 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Year: 2023

Type: supplementary-materials

Abstract: In vivo efficacy studies comparing PF-06463922 treatment at 10 mg/kg/day (5 mg/kg BID) and 3 mg/kg/day (1.5 mg/kg BID) with crizotinib treatment at 100 mg/kg QD in: A, Felix-PDX xenografts and B, SH-SY5Y xenografts.

DOI: 10.1158/2159-8290.22531688

Authors: Nicole R. Infarinato, Jin H. Park, Kateryna Krytska, Hannah T. Ryles, Renata Sano, Katherine M. Szigety, Yimei Li, Helen Y. Zou, Nathan V. Lee, Tod Smeal, Mark A. Lemmon, Yael P. Mossé

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362481361

Cites:

Cited by:

Related to: 10